Rituximab in two cases of Goodpasture's syndrome - PubMed (original) (raw)

Case Reports

Rituximab in two cases of Goodpasture's syndrome

Birgit Schless et al. NDT Plus. 2009 Jun.

Abstract

We describe the effects of rituximab in two patients with refractory Goodpasture's syndrome. After one single 1000 mg dose administration, rituximab did not appear to improve renal function in either of our cases. Polyoma virus-negative leukoencephalopathy, a probable toxic side effect of rituximab, was seen in our first patient.

Keywords: Goodpasture’s syndrome; anti-GBM disease; leukoencephalopathy; plasma exchange; rituximab.

PubMed Disclaimer

Figures

Fig. 1

Case 1. Cerebral t2-weighted MRI showing a triangular lesion of the corpus callosum with signs of leukoencephalopathy (arrow).

Fig. 2

Case 2. Levels of serum creatinine and anti-GBM antibodies before and during treatment with cyclophosphamide, prednisolone, plasmapheresis and rituximab (arrow).

Similar articles

• The clinical spectrum of acute glomerulonephritis and lung haemorrhage (Goodpasture's syndrome).
  Holdsworth S, Boyce N, Thomson NM, Atkins RC. Holdsworth S, et al. Q J Med. 1985 Apr;55(216):75-86. Q J Med. 1985. PMID: 4011844
• Inpatient Burden and Mortality of Goodpasture's Syndrome in the United States: Nationwide Inpatient Sample 2003-2014.
  Kaewput W, Thongprayoon C, Boonpheng B, Ungprasert P, Bathini T, Chewcharat A, Srivali N, Vallabhajosyula S, Cheungpasitporn W. Kaewput W, et al. J Clin Med. 2020 Feb 6;9(2):455. doi: 10.3390/jcm9020455. J Clin Med. 2020. PMID: 32041346 Free PMC article.
• [A giant cell arteritis revealing a Goodpasture's syndrome].
  Alix PM, Belloi A, Berthoux É, Dijoud F, Villar E, Pariset C. Alix PM, et al. Nephrol Ther. 2018 Apr;14(2):105-108. doi: 10.1016/j.nephro.2017.09.004. Epub 2017 Dec 28. Nephrol Ther. 2018. PMID: 29290619 French.
• Diagnosis and classification of Goodpasture's disease (anti-GBM).
  Hellmark T, Segelmark M. Hellmark T, et al. J Autoimmun. 2014 Feb-Mar;48-49:108-12. doi: 10.1016/j.jaut.2014.01.024. Epub 2014 Jan 21. J Autoimmun. 2014. PMID: 24456936 Review.
• Characteristics and outcomes of patients with Goodpasture's syndrome.
  Shah MK, Hugghins SY. Shah MK, et al. South Med J. 2002 Dec;95(12):1411-8. South Med J. 2002. PMID: 12597309 Review.

Cited by

• The Immunobiological Agents for Treatment of Antiglomerular Basement Membrane Disease.
  Yamashita M, Takayasu M, Maruyama H, Hirayama K. Yamashita M, et al. Medicina (Kaunas). 2023 Nov 16;59(11):2014. doi: 10.3390/medicina59112014. Medicina (Kaunas). 2023. PMID: 38004064 Free PMC article. Review.
• Rituximab for the treatment of refractory anti-glomerular basement membrane disease.
  Yang XF, Jia XY, Yu XJ, Cui Z, Zhao MH. Yang XF, et al. Ren Fail. 2022 Dec;44(1):1123-1129. doi: 10.1080/0886022X.2022.2097405. Ren Fail. 2022. PMID: 35820833 Free PMC article.
• Relapse of treated anti-GBM disease following hair dye use.
  Povey J, Rutherford E, Levy J, Muniraju T. Povey J, et al. BMJ Case Rep. 2021 Apr 1;14(4):e240543. doi: 10.1136/bcr-2020-240543. BMJ Case Rep. 2021. PMID: 33795274 Free PMC article.
• Use of Rituximab in Management of Rapidly Progressive Glomerulonephritis.
  Cancarevic I, Malik BH. Cancarevic I, et al. Cureus. 2020 Jan 30;12(1):e6820. doi: 10.7759/cureus.6820. Cureus. 2020. PMID: 32181067 Free PMC article. Review.
• Rituximab in treatment of anti-GBM antibody glomerulonephritis: A case report and literature review.
  Uematsu-Uchida M, Ohira T, Tomita S, Satonaka H, Tojo A, Ishimitsu T. Uematsu-Uchida M, et al. Medicine (Baltimore). 2019 Nov;98(44):e17801. doi: 10.1097/MD.0000000000017801. Medicine (Baltimore). 2019. PMID: 31689860 Free PMC article. Review.

References

1. 1. Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967;126:989–1004. - PMC - PubMed
2. 1. Wang XP, Fogo AB, Colon S, et al. Distinct epitopes for anti-glomerular basement membrane alport alloantibodies and goodpasture autoantibodies within the noncollagenous domain of alpha3(IV) collagen: a janus-faced antigen. J Am Soc Nephrol. 2005;16:3563–3571. - PubMed
3. 1. Levy JB, Turner AN, Rees AJ, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134:1033–1042. - PubMed
4. 1. Lockwood CM, Boulton-Jones JM, Lowenthal RM, et al. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. Br Med J. 1975;2:252–254. - PMC - PubMed
5. 1. Gonzales-Stawinski GV, Yu PB, Parker W, et al. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti CD20 monoclonal antibody. Clin Immunol. 2001;98:175–179. - PubMed

Publication types

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central